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GPCR signalingThe precise mechanism(s) by which intracellular TOLL-like receptors (TLRs) become activated by their
ligands remains unclear. Here, we report a molecular organizational G-protein coupled receptor (GPCR) sig-
naling platform to potentiate a novel mammalian neuraminidase-1 (Neu1) and matrix metalloproteinase-9
(MMP-9) cross-talk in alliance with neuromedin B GPCR, all of which form a tripartite complex with TLR-7
and -9. siRNA silencing Neu1, MMP-9 and neuromedin-B GPCR in RAW-blue macrophage cells signiﬁcantly
reduced TLR7 imiquimod- and TLR9 ODN1826-induced NF-κB (NF-κB-pSer536) activity. Tamiﬂu, speciﬁc
MMP-9 inhibitor, neuromedin B receptor speciﬁc antagonist BIM23127, and the selective inhibitor of
whole heterotrimeric G-protein complex BIM-46174 signiﬁcantly block nucleic acid-induced TLR-7 and -9
MyD88 recruitment, NF-κB activation and proinﬂammatory TNFα and MCP-1 cytokine responses. For the
ﬁrst time, Neu1 clearly plays a central role in mediating nucleic acid-induced intracellular TLR activation,
and the interactions involving NMBR–MMP9–Neu1 cross-talk constitute a novel intracellular TLR signaling
platform that is essential for NF-κB activation and pro-inﬂammatory responses.
© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-SA license. 1. Introduction
Dimerization of the extracellular domain of most mammalian
TOLL-like receptors (TLRs) is essential for their ligand induced activa-
tion. However, the mechanism(s) by which TLRs become activated by
this process is not well understood. For the majority of TLR receptors,
dimerization is a prerequisite to facilitate MyD88/TLR complex for-
mation and subsequent cellular signaling to activate NF-κB. However,
the parameters controlling interactions between the receptors and
their ligands remained poorly deﬁned until now. For the cell-surface
TLRs, we have identiﬁed a novel molecular organizational G-protein
coupled receptor (GPCR) signaling platform to potentiate Neu1
sialidase and matrix metalloproteinase-9 (MMP9) cross-talk inA, 2′-(4-methylumbelliferyl)-
osphate; MMP, matrix metal-
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nc. Open access under CC BY-NC-SA licregulating endotoxin lipopolysaccharide (LPS) induced TLR4 recep-
tors and cellular function [1–3]. In addition, the activity of these
TLRs is also regulated by a variety of other ligand-related cofactors in-
volved in improving ligand recognition by the receptors such as
diacylglyceride sensing by CD36 [4,5], CD14 [6], andMD-2 [7,8]. How-
ever, there is another subset of TLRs, namely TLR-3, -7, -8, and -9,
which are localized within the endosomal compartment of the cell
that are known to recognize nucleic acids [9]. Although their subcel-
lular compartmentalization and cellular distribution are maintained
in their correct subcellular localization by endoplasmic reticulum
(ER) chaperone gp96 [10], protein associated with TLR4 (PRATA/B)
[11–13], the ER membrane protein, UNC93B [14,15], and the
high-mobility group protein B1 (HMGB1) [16], the mechanistic ma-
chinery driving nucleic acid-induced intracellular TLR dimerization
and subsequent receptor function is unknown.
To gain an insight into the molecular mechanism of intracellular
TLR7 triggering, Visintin and colleagues using N-nitrose-N9-ethyl
urea (ENU)-induced mutations in mice identiﬁed a crucial role for
N-glycosylation target sequence in position 66–68 (N66) within the
leucine-rich repeat, LRR1 ectodomain, containing a putative glycan
acceptor site, which resulted in the conversion of threonine 68 to iso-
leucine (T68I) in TLR7 [17]. This TLR7rsq1 mutation was found to re-
side in the N-terminal portion of TLR7, which was found to be in
close proximity to the ﬁrst two insertions thought to be relevant for
ligand binding. The abrogation of the N-glycosylation consensusense. 
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molecular weight TLR7 agonist resiquimod (R848), but not its ability
to bind to ssRNA. This unexpected ssRNA binding by the mutant
TLR7rsq1 and lack of signaling implied that the N-glycosylation status
of the N-terminal portion of TLR7 is essential for receptor activation
and function [17].
In conjunction with the TLR dimerization process, TLR receptors
need to undergo conformational changes following ligand binding,
which allow proper orientation of the ectodomains of TLR for recep-
tor association [18,19]. Indeed, ligand-induced conformational
changes have been shown to allosterically activate TLR9 receptors
[20]. Using mutagenesis studies on murine TLR-7 and -9, others
have shown sensitivity of these receptors to subtle changes [21]. In
another study, we reported the importance of the involvement of
α-2,3-sialyl residues linked to β-galactosides in establishing steric
hindrance to TLR4 dimerization [22,23]. This novel premise was em-
phasized by exogenous α-2,3-sialyl speciﬁc neuraminidases [23]. Pri-
mary bone marrow macrophages derived from Neu1-deﬁcient mice
treated with a puriﬁed recombinant neuraminidase (Clostridium
perfringens) or recombinant Trypanosoma cruzi trans-sialidase (TS)
but not the mutant TSΔAsp98-Glu induced phosphorylation of
NF-κB [23]. These results are consistent with our other reports
[23–27] supporting the glycosylation model in corroborating the im-
portance of sialyl α-2,3-linked β-galactosyl residues of TLRs as well as
for tyrosine receptor kinase Trks in the initial stages of ligand-induced
receptor activation. For mammalian sialidases, we have shown that
the mammalian neuraminidase-1 (Neu1) desialylation of α-2,3-
sialyl residues of cell-surface TLR receptors enables receptor dimer-
ization [23]. Neu1 was found to be an important intermediate in the
initial process of TLR ligand-induced receptor activation and subse-
quent cell function [23,24]. Central to this process is that Neu1,
and not the other three mammalian sialidases, forms a complex
with either TLR-2, -3 or -4 cell-surface receptors in naive TLR-
expressing cells or primary macrophage cells [24]. The prerequisite
desialyation of cell-surface TLR receptors caused by activated Neu1
enables MyD88/TLR4 complex recruitment, NFκB activation and
pro-inﬂammatory responses [23,24].
This report describes the key players involved in the activation of
nucleic acid sensing intracellular TLR-7 and TLR-9 receptors against
imiquimod and CpG oligodeoxynucleotide (ODN), respectively. It
discloses a striking identical signaling paradigm as described for the
cell-surface TLRs [1–3]. Here, Neu1 and MMP9 cross-talk in alliance
with GPCR neuromedin-B receptors tethered to TLR-7 and -9 recep-
tors at the ectodomain forms a novel molecular organizational
GPCR signaling platform that is essential for ligand activation of
the TLRs and cellular signaling. Since TLR9 receptors are prone to
ligand-induced conformational changes in the ectodomains [20],
it is proposed here that ligand binding to TLR-7 and -9 receptors
initiates a conformational change to potentiate G-protein coupled
receptor (GPCR)-signaling via membrane Gα subunit proteins and
matrix metalloproteinase-9 (MMP-9) activation to induce Neu1.
Activated Neu1 speciﬁcally hydrolyzes α-2,3-sialyl residues linked to
β-galactosides, the structural perturbation of which would trigger
dimeric receptor complex formation to facilitate MyD88/TLR recruit-
ment and subsequent pro-inﬂammatory cell responses. These ﬁndings
radically redeﬁne the current dogma(s) governing the essential acti-
vating molecules tethered to nucleic acid sensing TLRs, which may
provide pioneering molecular targeting approaches to disease inter-
vention strategies.
2. Materials and methods
2.1. Cell lines
The HEK-TLR7-HA cells were obtained by stable transfection of
HEK293XL cells with the pUNO-hTLR7-HA plasmid which expressesthe human TLR7 gene fused at the 3′ end to the inﬂuenza hemagglu-
tinin (HA) (InvivoGen, San Diego, CA). HEK-293 (ATCC® CRL-1573™)
were obtained from American Type Culture Collection (Manassas,
VA 20110 USA). The cells were grown at 37 °C in 5% CO2 in cul-
ture media containing Dulbecco's Modiﬁed Eagle Medium (DMEM)
(Gibco, Rockville, MD) supplemented with 10% fetal calf serum (FCS)
(HyClone, Logan, Utah, USA) and selection in 100 μg/mL Normocin™.
The HEK-293 cells were grown in the same medium without selection
antibiotic.
RAW-Blue™ cells (Mouse Macrophage Reporter Cell Line,
InvivoGen, San Diego, CA) derived from RAW 264.7 macrophages
are grown in culture medium containing Zeocin as the selectable
marker. They stably express a secreted embryonic alkaline phospha-
tase (SEAP) gene inducible by NF-κB and AP-1 transcription factors.
Upon stimulation, RAW-Blue™ cells activate NF-κB and/or AP-1 lead-
ing to the secretion of SEAP which is detectable and measurable using
QUANTI-Blue™, a SEAP detection medium (InvivoGen). RAW-Blue™
cells are resistant to Zeocin™ and G418 in the conditioned medium.
RAW264.7 cells were obtained from Dr Andrew Craig (Queen's
University) and maintained in DMEM with 10% FCS and 2 mM
L-glutamine at 37 °C in 5% CO2 humidiﬁed incubator.
2.2. Silencing Neu1, MMP-9 and NMBR mRNA using siRNA
Mouse NEU1, MMP9 and NMBR ON-TARGETplus SMART pool,
were obtained from Thermo Scientiﬁc Dharmacon each containing a
mixture of four predesigned siRNAs targeting one gene. RAW-blue
cells were plated in 6-well plate at 3 × 105 cells/well and incubated
at 37 °C for 24 h or until 50–60% conﬂuent. 250 μL OPTIMEM media
(Invitrogen) was pipetted into each of 2 tubes, 100 pmol siRNA was
added to one tube and 6 μL Lipofectamine 2000 (Invitrogen) into
the other and incubated for 5 min. The Lipofectamine containing
tube was transferred into the siRNA containing tube by gently mixing.
The mixture was incubated for 20 min at room temperature. During
the 20 min incubation, medium was aspirated from the wells
containing the cells and replaced with 500 μL of fresh OPTIMEM
media and the mixture containing siRNA duplex together with
Lipofectamine 2000 complexes was added to each well incubating
for 5–6 h at 37 °C in a humidiﬁed 5% CO2 incubator. At the end of
transfection, the mixture is replaced with fresh complete media and
plate is incubated for 24 h. The process of siRNA transfection was re-
peated on these same transfected cells. The transfection efﬁciency of
90% was determined using ﬂuorescein conjugated control siRNAs
(Santa Cruz Biotech) and counting the proportion of labeled cells
using ﬂuorescence microscopy (Zeiss Imager M2). 72 h post double
siRNA transfection, RAW-blue cells were assayed for protein level to
assess silencing.
2.3. Ligands
TLR7 ligand, Imiquimod from BioVision was used at 10 or 20 μg/mL.
TLR9 ligand, ODN 1826 from InvivoGen was used at 10 or 20 μg/mL.
ODN 1826 is a type B CpG ODN speciﬁc for mouse TLR9. Type B CpG
ODNs contain a full phosphorothioate backbone with one or more
CpG dinucleotides. They strongly activate B cells but weakly stimulate
IFN-α secretion.
2.4. Inhibitors
Tamiﬂu (pure oseltamivir phosphate, Hoffmann-La Roche Ltd.,
Mississauga, Ontario, Lot # S00060168) was used at indicated con-
centrations. MMP-3 inhibitor (MMP3i; stromelysin-1 inhibitor,
Calbiochem-EMD Chemicals Inc.) inhibits MMP-3 (IC50 = 5 nM).
MMP-9 inhibitor (MMP9i, Calbiochem-EMD Chemicals Inc.) is a
cell-permeable, potent, selective, and reversible MMP-9 inhibitor
(IC50 = 5 nM). It inhibits MMP-1 (IC50 = 1.05 μM) and MMP-13
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G-protein inhibitor kindly provided by IPSEN Innovation (91940 Les
Ulis, France). BIM-23127 is a speciﬁc neuromedin B receptor inhibitor
from Tocris Bioscience (Tocris House, IO Centre Moorend Farm
Avenue, Bristol, BS11 0QL, United Kingdom).
2.5. NF-κB-dependent secretory alkaline phosphatase (SEAP) assay
Brieﬂy, a cell suspension of 1 × 106 cells/mL in fresh growth me-
dium was prepared, and 100 μL of cell suspension (∼100,000 cells)
was added to each well of a Falcon ﬂat-bottom 96-well plate (Becton
Dickinson). Different concentrations of either speciﬁc MMP9 inhibitor
(MMP9i) common Tamiﬂu or BIM-46174 were added to each well 1 h
before ligand stimulation. The plates were incubated at 37 °C in a 5%
CO2 incubator for 18–24 h. A QUANTI-Blue™ (InvivoGen) solution
which is a detection medium developed to determine the activity
of any alkaline phosphatase present in a biological sample was pre-
pared following the manufacturer's instructions. Brieﬂy, 160 μL of
resuspended QUANTI-Blue solution was added to each well of a
ﬂat-bottom 96-well plate, followed by 40 μL of supernatant from
stimulated RAW-blue cells. The plate was incubated for 60 min at
37 °C and the SEAP levels were determined using a spectrophotome-
ter at 620–655 nm. Each experiment was performed in triplicates.
2.6. Co-immunoprecipitation
Macrophage cells were left cultured in media or in media
containing 20 μg/mL imiquimod or ODN for indicated time intervals.
Cells (1 × 107 cells) are pelleted and lysed in lysis buffer (50 mM
Tris, pH 8, 150 mMNaCl, 1%NP-40, 0.2 mg/mL) containingHalt Prote-
ase and Phosphatase Inhibitor cocktail (Thermo Scientiﬁc). For immu-
noprecipitation, Neu1, MMP-9, TLR7, TLR9 or NMBR in cell lysates
from RAW-blue cells are immunoprecipitated with 1.0 μg of either
rabbit anti-Neu1, rabbit anti-MMP-9, rabbit anti-TLR7, rabbit anti
TLR9 or rabbit anti-NMBR antibodies for 24 h. Following immunopre-
cipitation, complexes are isolated using protein A or Gmagnetic beads,
washed 3× in buffer (10 mM Tris, pH 8, 1 mM EDTA, 1 mM EGTA,
150 mM NaCl, 1% Triton X-100 and 0.2 mM sodium orthovanadate)
and resolved by 8% gel electrophoresis (SDS-PAGE). Proteins are
transferred to polyvinylidene ﬂuoride (PVDF) transfer membrane
blot. The blots are probed for either MMP-9 with anti-MMP-9
(H-129, Santa Cruz Biotechnology, Inc. CA), Neu1 with anti-Neu1
(H-300, Santa Cruz Biotech), TLR7 with anti-TLR7 (H-114, Santa Cruz
Biotech), TLR9 with anti TLR9 (H-100, Santa Cruz Biotechnology) or
NMBR with anti-NMBR (M-52, Santa Cruz Biotechnology) followed
by HRP conjugated secondary IgG antibodies or Clean-Blot IP Detec-
tion Reagent for IP/Western blots (Pierce Biotechnology, Thermo Fish-
er Scientiﬁc, Rockford, IL) andWestern Lightning Chemiluminescence
Reagent Plus. The chemiluminescence reaction was analyzed with
X-ray ﬁlm. Sample concentration for gel loading was determined by
the Bradford reagent (Sigma-Aldrich Canada Ltd., Oakville, Ontario).
2.7. Neu1 or MMP9 colocalization with TLR-7 and -9
RAW-bluemacrophage cells were cultured in DMEMmediumwith
10% FCS. Cells were treated with 20 μg/mL imiquimod or 20 μg/mL
ODN for 30 min or left untreated as controls. Cells were ﬁxed, perme-
abilized and immunostained with either rabbit anti-TLR7 (H-114,
Santa Cruz Biotech) or rabbit anti-TLR9 (H-100, Santa Cruz Biotech)
and goat anti-MMP-9 (M-17, Santa Cruz Biotechnology) or goat
anti-Neu1 (N-20, Santa Cruz Biotechnology) followed with Alexa
Fluor488 donkey anti-rabbit IgG or Alexa Fluor594 donkey anti-goat
IgG. Stained cells were visualized using a Zeiss M2 Imager with a
40× objective. Images were processed using Image J 1.38x software
(NIH, USA). To calculate the amount of colocalization in the selectedimages, the Pearson correlation coefﬁcient was measured and ex-
pressed as a percentage using Image J 1.38x software.
2.8. GPCR neuromedin-B receptor (NMBR) colocalization with Rab7
RAW-blue mouse macrophage cells were cultured in DMEMmedi-
um with 10% FCS. Cells were ﬁxed, permeabilized and immuno-
stained with rabbit anti-NMBR (M-52, Santa Cruz Biotechnology,
Inc., California, USA) and mouse monoclonal anti-Rab7 (Abcam)
followed with Alexa Fluor568 donkey anti-mouse IgG or Alexa
Fluor488 donkey anti-rabbit IgG. Stained cells were visualized using
a Zeiss M2 Imager with a 40× objective. Images were captured and
processed using Image J 1.38x software (NIH, USA). To calculate the
amount of colocalization in the selected images, the Pearson correla-
tion coefﬁcient was measured and expressed as a percentage using
Image J 1.38x software.
2.9. Bio-Plex cytokine microarray proﬁles in the cell culture supernatants
using the multiplex bead-based assay
RAW-blue mouse macrophage cells were grown at 3 × 104 cells/
well in ﬂat-bottom 96-well plate at 37 °C and 5% CO2 for 18–24 h.
Media was discarded and 100 μL of fresh media alone or with inhibi-
tors at indicated concentrations was added to the wells, and the plate
was incubated for 60 min before adding the speciﬁc ligand. The plate
was incubated for an additional 24 h. Supernatants were collected
and the assay was carried out according to the manufacturer's in-
structions. The cytokines in individual supernatant samples were
measured using the Bio-Plex 200 System and quantiﬁed using stan-
dard curve for each cytokine.
2.10. Statistics
Comparisons between two groups were made by one-way ANOVA
at 95% conﬁdence using unpaired t-test and Bonferroni's Multiple
Comparison Test or Dunnett's Multiple Comparison Test for compari-
sons among more than two groups.
3. Results
3.1. Neu1 and MMP-9 cross-talk is tethered to naive full-length and
cleaved TLR7 receptors
According to the trafﬁcking and processing models of intracellular
TLRs [9], TLR3, TLR7, TLR8, TLR9, and probably TLR13 of mice, are
expressed within the endoplasmic reticulum (ER), endosomes,
multi-vesicular bodies, and lysosomes. However, ligand-induced TLR
activation only occurs within acidiﬁed endolysosomal compartments.
Upon reaching these acidiﬁed compartments, the TLR9 ectodomain is
proteolytically cleaved by proteases [28,29]. However, the full-length
TLR9 is found only in the ER, whereas the cleaved, biologically active
product is restricted to endolysosomes. Multiple proteases have been
implicated in TLR9 cleavage, including various cathepsins and aspar-
agine endopeptidase [28–33] as well as asparagine endopeptidase
cleavage of TLR7 [34].
For cell-surface TLR4 receptors, we reported a receptor signaling
paradigm involving a process of receptor ligand-induced GPCR-
signaling via Gαi-proteins, MMP-9 activation, and the induction of
Neu1 activation [2]. To test whether this signaling paradigm is in-
volved with full-length and cleaved intracellular TLRs, we initially
asked whether Neu1 and MMP9 form a complex with TLR7 receptors.
Co-immunoprecipitation experiments using cell lysates from HEK-
TLR7-HA cells demonstrated that both Neu1 and MMP-9 are tethered
to full-length (120 kDa) and cleaved (72 kDa) TLR7 receptors in
naive and 30 min imiquimod stimulated cells (Fig. 1A and B). Howev-
er, only Neu1 and Neu4 but not Neu-2 and -3 co-immunoprecipitated
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(Fig. 1B). Recent reports by us have indicated that Neu4 is tethered to
MMP9 but requires a special ligand to become activated [35,36]. In
support of the co-immunoprecipitation results with HEK-TLR7-HA
cells, the data shown in Fig. 1C–D validated the predicted association
of Neu1 and MMP9 with TLR7. Zeiss M2 Imager ﬂuorescence micros-
copy revealed the endosomal colocalization of Neu1 and MMP9 with
TLR7 in naive and imiquimod-treated RAW-blue cells. There was no
marked reduction of Neu1 (30.8% overlay) andMMP9 (47.0% overlay)
colocalization with TLR7 in these cells treated with imiquimod for
60 min compared with the untreated control cells (33.4% overlay
for Neu1 and 40.9% for MMP9). As predicted, Neu1 and the active
65 kDa isoform of MMP9 also co-immunoprecipitated with TLR7Fig. 1. TLR7 co-immunoprecipitates with Neu1 and MMP9 and conversely vice-versa. HEK
containing 10 μg/mL imiquimod for 30 min or indicated times. Cells (1 × 107 cells) were p
lysates from either HEK-TLR7-HA or RAW-blue cells were immunoprecipitated with 1 μg
Following immunoprecipitation, complexes were isolated using protein A or G magnetic b
HA with anti-HA or TLR7 with anti-TLR7 antibodies followed by Clean-Blot IP Detection R
The chemiluminescence reaction was analyzed with X-ray ﬁlm. Sample concentration for
out of three independent experiments showing similar results. (B) Neu1 co-immunoprecip
lysed in lysis buffer and the protein lysates were resolved by SDS-PAGE. The blots were pro
DMSO in PBS before lysing to control for the effect of imiquimod reagent diluent. (C) Neu1
circular glass slides in culture media containing 10% fetal calf sera for 24 h and treated with
abilized and immunostained with rabbit anti-TLR7 and goat anti-Neu1 or goat anti-MMP9 fo
IgG. Stained cells were visualized using a Zeiss M2 imager with a 40× objective. To calculat
ﬁcient was measured on a total of 15–20 cells per image and expressed as a percentage us
experiments showing similar results. (G) Western blot of TLR-4 and -9 expressions in th
were pelleted and lysed in lysis buffer. The TLR9 and TLR4 receptors in the cell lysates were s
β-Actin was used as an internal control protein for loading of the cell lysate. The data a
(H) Western blot analysis of ODN- and imiquimod-induced phosphorylated NF-κB (Ser(P)5
either 10 μg/mL imiquimod or 10 μg/mL ODN for 30 min or left untreated as media control.
by SDS-PAGE, and the blot was probed with phospho-speciﬁc polyclonal rabbit antibody ag
was used as an internal control protein for loading of the cytoplasmic cell lysate. The datain cell lysates from naive and imiquimod-treated RAW-blue cells
with no diminution of Neu1 and MMP9 after 15–60 min (Fig. 1E).
Conversely, the cleaved 72 kDa and possibly 65 kDa TLR7 co-
immunoprecipitated with both Neu1 and MMP9 in cell lysates from
naive and 30 min imiquimod-treated RAW-blue cells (Fig. 1F).
3.2. TLR7 and TLR9 signaling is independent of TLR4
A recent report has demonstrated that ODN stimulation of
human lung cancer cells induced the secretion of high-mobility group
protein B1 (HMGB1) dose-dependently [37]. The cell response to
HMGB1 stimulation acting synergistic with ODN mediated a MyD88-
dependent up-regulation of MMP2, MMP9 and cyclin-dependent-TLR7-HA (A) and RAW-blue (E and F) cells were left cultured in media or in media
elleted and lysed in lysis buffer. Neu1, MMP9, TLR7-HA and TLR7 receptors in the cell
of rabbit anti-Neu1, rabbit anti-MMP9 or 1 μg of rabbit anti-HA antibodies for 24 h.
eads, washed 3× in buffer and resolved by 8% SDS-PAGE. The blots were probed for
eagent for IP/Western blots and Western Lightning Chemiluminescence Reagent Plus.
gel loading was determined by Bradford assay. The data are a representation of one
itates withTLR7. HEK-TLR7-HA cells were used as described in (A). They were pelleted,
bed with antibodies against the indicated proteins. DMSO/PBS: cells were treated with
and MMP9 colocalize with TLR7. RAW-blue cells (50,000 cells) were plated on 12 mm
10 μg/mL imiquimod for 60 min or left untreated as controls. Cells were ﬁxed, perme-
llowed with Alexa Fluor488 donkey anti-rabbit IgG or Alexa Fluor594 donkey anti-goat
e the percentage of colocalization in the selected images, the Pearson correlation coef-
ing Image J 1.38x software. The data are a representation of one of three independent
e cell lysates of HEK-293 and HEK-TLR7-HA cells. Unstimulated cells (1 × 107 cells)
eparated by SDS-PAGE, and the blot was probed with anti-TLR9 or anti-TLR4 antibodies.
re a representation of one of two independent experiments showing similar results.
36) in cytoplasmic cell lysates. HEK-293 and HEK-TLR7-HA cells were stimulated with
Cells (1 × 107 cells) were pelleted and lysed in lysis buffer. Cell lysates were separated
ainst NF-κB (Ser(P)536) with minimal reactivity with non-phosphorylated p65. β-Actin
are a representation of one of two independent experiments showing similar results.
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the receptor for advanced glycation endproducts and TLR4 [37]. If
ODN-induces HMGB1 secretion in these cancer cells, we askedwhether
HMGB1 might have a role in the ODN-induced NFκB activation via a
TLR4 intermediary in our studies. To test this important question, we
initially performed Western blot analyses of HEK-TLR7-HA and
HEK-293 cells for TLR4 and TLR9 expressions in the cell lysates followed
with NFκB activation associated with ODN- and imiquimod-treated
cells. Optimal activation of NF-κB requires phosphorylation in the
transactivation domain of p65. This transactivation domain of p65
subunit is responsible for the interactionwith the inhibitor IκB and con-
tains the phosphorylation sites. A phospho-speciﬁc polyclonal antibody
against the human NF-κB pSer536 that has minimal reactivity with
non-phosphorylated p65 was used here. The data shown in Fig. 1G
clearly indicate that HEK-293 and HEK-TLR7-HA cells express TLR9
but not TLR4 receptors. In Fig. 1H, the data indicate that ODN and
imiquimod induce the 65 kDa NFκB pSer539 phosphorylation in these
cells, which did not involve the TLR4 as an intermediary. These results
are consistent with another reported ﬁnding [38].
3.3. Inhibitory effect of Tamiﬂu, MMP9 inhibitor, a neuromedin B
receptor speciﬁc antagonist BIM23127, and a selective inhibitor of whole
heterotrimeric G-protein complex BIM46174 on imiquimod-induced
phosphorylation of NF-κB
To gain insight into the mechanism of action of these nucleic acid
sensing receptors, we used RAW-blue cells and asked whether inhib-
itors of Neu1 and MMP9 would block MyD88 recruitment, phosphor-
ylation of NF-κB and subsequent SEAP secretion associated with
imiquimod- or ODN-treated cells. The data shown in Fig. 2C indicate
a differential optimal activation of NF-κB associated with imiquimod
and ODN treated RAW-blue cells. Cells treated with imiquimod in-
duced optimal NF-κB pSer536 activity after 30 min followed by a con-
comitant decline at 45 and 60 min. However, ODN induced NF-κB
pSer536 activity after 45 min with a marked decline after 60 min of
treatment.
The inhibitory effect of Tamiﬂu, MMP9 inhibitor (MMP9i), a
neuromedin B GPCR speciﬁc antagonist BIM23127, and a selective in-
hibitor of the whole heterotrimeric G-protein complex named
BIM-46174 [39], an imidazo-pyrazine derivative, on imiquimod-
induced NFκB phosphorylation was also examined in RAW-blue mac-
rophage cells. The data shown in Fig. 2D show that these speciﬁc com-
pounds inhibited imiquimod-induced NF-κB pSer536 activation in
these cells comparable to the no ligand control levels and compared
with the imiquimod positive control.
3.4. Interference Neu1, MMP-9 and neuromedin B (NMBR) using siRNA
knockdown
To further conﬁrm the role of Neu1, MMP9 and heterotrimeric
G-protein NMBR complex in imiquimod-induced NF-κB pSer536 acti-
vation, we transfected RAW-blue cells with either siRNA Neu1,
siRNA MMP9 or siRNA NMBR using ON-TARGETplus SMART pool,
each containing a mixture of four predesigned siRNAs targeting one
gene using OPTIMEM media and Lipofectamine 2000 reagent. Previ-
ously, we reported that when using this transfection protocol,
Western blot analyses of whole cell lysates from siRNA MMP9 KD
RAW-blue cells revealed a complete knockdown of the active
88 kDa isoform of MMP9 compared to the wild-type (WT) control,
but there appeared to be a pro-active MMP-9 (105 kDa) protein frag-
ment that was still present [2]. Western blot analyses of the WT and
siRNA Neu1 KD, MMP9 KD and NMBR KD in RAW-blue cells revealed
a complete reduction of 65 kDa NF-κB pSer536 protein levels in the
cell lysates from imiquimod-treated siRNA KD cells compared to the
WT controls and β-actin (Fig. 2D). Scrambled siRNA had no effect
on 30 min imiquimod-induced NF-κB pSer536 levels using theparental RAW264.7 cells (Fig. 2E). Western blot analyses of whole
cell lysates from siRNA NMBR KD (Fig. 2F) and siRNA Neu1 KD
(Fig. 2G) RAW-blue cells revealed a marked knockdown of the three
isoforms of NMBR as well as Neu1 compared to the WT and scram-
bled siRNA controls. For siRNA MMP9 KD, we reported using western
blot analyses of whole cell lysates that siRNA MMP9 KD RAW-blue
cells revealed a complete knockdown of the active 88-kDa isoform
of MMP9 compared with the WT results, but there appeared to be a
proactive 105 kDa MMP9 isoform present [2].
3.5. Tamiﬂu, MMP9i and neuromedin B GPCR antagonist BIM-23127 in-
hibit imiquimod-induced TLR7 recruitment of adaptor molecule MyD88
in RAW-blue cells
Since Tamiﬂu, MMP9i and GPCR antagonist BIM23127 inhibit
imiquimod-induced NF-κB pSer536 activation in RAW-blue cells
(Fig. 2D), we further assessed if they would inhibit imiquimod-
mediated recruitment of the adaptor molecule MyD88 to TLR7. Our
data clearly show this to be the case. MyD88 co-immunoprecipitated
with the 65 kDa cleaved TLR7 receptor following stimulation with
imiquimod for 30 min, and this co-IP effect was blocked by Tamiﬂu,
MMP9i and BIM23127 (Fig. 3A). It is well known that both TLR-7
and -9 are completely dependent upon MyD88 in eliciting a signal
[9], and our data are consistent with this model. However, the pro-
cess(es) by which nucleic acid sensing TLRs undergo ligand-induced
conformational changes to make them competent to signal is not
well understood. For an efﬁcient TLR7 signaling, cleavage of the TLR7
receptor is required for ligand binding and subsequent association
with MyD88. Our data here provide evidence for another level of
ligand-induced TLR activation. They support an unprecedented
unique organizational GPCR signaling platform tethered to TLR7 re-
ceptors as the initial processing stage for imiquimod-induced activa-
tion of these receptors and subsequent recruitment of the adaptor
molecule MyD88.
To conﬁrm Neu1 and MMP9 linkage with imiquimod-induced
NFκB activation, we also performed the NFκB-dependent secretory
alkaline phosphatase (SEAP) assay. RAW-blue cells stably express a
SEAP gene inducible by NF-κB and AP-1 transcription factors leading
to the secretion of SEAP. Secreted SEAP is detectable and measurable
using QUANTI-Blue substrate. Here, we used Tamiﬂu, MMP9i, the spe-
ciﬁc inhibitor of MMP3 (MMP3i) and BIM-46174 antagonist of the
whole heterotrimeric G-protein complex to determine their inhibitory
effects on imiquimod-induced NF-κB activation and subsequent SEAP
activity in live RAW-blue cells. The NFκB-dependent SEAP assay
shown here clearly demonstrated that BIM-46174 (IC50 = 7.94 μM)
(Fig. 3B), MMP9i (IC50 = 100 μM) and Tamiﬂu (IC50 = 240 μM)
(Fig. 3C) dose-dependently attenuated SEAP activity compared with
a lack of inhibition with MMP3i (IC50 N 1000 μM) (Fig. 3B) associated
with imiquimod-treated live RAW-blue cells.
3.6. Neu1 and MMP-9 cross-talk is essential for TLR9 receptor activation
and cellular signaling
If Neu1 andMMP-9 complex is tethered to TLR7 receptors, we asked
whether they would also colocalize with TLR9 receptors. Fluorescence
microscopy revealed the intracellular colocalization of Neu1 and
MMP-9 with TLR9 in naive and ODN-treated RAW-blue cells (Fig. 4A
and B). Surprisingly, ODN treatment of these cells did not increase the
colocalization of TLR9 and MMP-9 (Fig. 4B). Co-immunoprecipitation
experiments using cell lysates from RAW-blue cells further dem-
onstrated that Neu1 forms a complex with TLR9 receptors in naive
and ODN treatment of cells for 30 min (Fig. 4C). In addition, the two
active isoforms of MMP9 (65 and 88 kDa) were found to co-
immunoprecipitate with TLR9 in the cell lysates of naive and 30 min
ODN-treated RAW-blue cells (Fig. 4C), and conversely, the cleaved
Fig. 2. (A) Western blot analysis of imiquimod- and ODN-induced phosphorylated NF-κB (Ser(P)536) in cytoplasmic cell lysates. RAW-blue cells were treated with either 10 μg/mL
imiquimod or 10 μg/mL ODN for the indicated times or left untreated as media control. Cells (1 × 107 cells) were pelleted and lysed in lysis buffer. Cell lysates were separated by
SDS-PAGE, and the blot was probed with phospho-speciﬁc polyclonal rabbit antibody against NF-κB (Ser(P)536). β-Actin was used as an internal control protein for loading of the
cytoplasmic cell lysate. Quantitative analysis was done by assessing the density of a band corrected for background in each lane using Corel Photo Paint 8.0 software. Each bar in the
graphs represents the mean ratio of NF-κB (Ser(P)536) to β-actin of band density ± S.E. (error bars) for 5–10 replicate measurements. The data are a representation of one of three
independent experiments showing similar results. (C) Western blot analysis of imiquimod-induced phosphorylated NF-κB (Ser(P)536) in cytoplasmic cell lysates from wild-type
(WT) and siRNA knockdown (KD) cells. RAW-blue macrophage cells were pretreated with 200 μM Tamiﬂu, 100 μg/mL MMP9i, 100 μg/mL BIM-23127 or 20 μM BIM-46174 for
30 min followed by 10 μg/mL imiquimod. RAW-blue siRNA KD Neu1, siRNA KD MMP9 and siRNA KD NMBR cells were treated with 10 μg/mL imiquimod. Cell lysates from the
WT and KD cells were separated by SDS-PAGE, and the blot was probed with phospho-speciﬁc polyclonal rabbit antibody against NF-κBp65-Ser(P)536. (D) RAW-blue cells were
transfected with scrambled siRNA and stimulated with10 μg/mL imiquimod. β-Actin was used as internal control proteins for loading of the cell lysate and scrambled siRNA
transfected cells for transfection control. The data in (C) and (D) are a representation of one of three independent experiments showing similar results. Western blot of NMBR
(D) and Neu1 (E) expressions in the cell lysates of unstimulated, scrambled siRNA, NMBR siRNA KD and Neu1 siRNA KD RAW-blue cells. Cells (1 × 107 cells) were pelleted and
lysed in lysis buffer. The NMBR and Neu1 proteins in the cell lysates were separated by SDS-PAGE, and the blot was probed with anti-NMBR or anti-Neu1 antibodies. β-Actin
was used as an internal control protein for loading of the cell lysate. The data are a representation of one of two independent experiments showing similar results.
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Neu1 and MMP9 in the same cell lysates (Fig. 4D).
At the genetic level, Western blot analyses of the WT and siRNA
Neu1 KD, MMP9 KD and NMBR KD in RAW264.7 cells revealed a sig-
niﬁcant reduction of 65 kDa NF-κB pSer536 protein levels in the cell ly-
sates associated with ODN-treated cells compared to the WT controls
and β-actin (Fig. 4E). Scrambled siRNA had no signiﬁcant effect on
ODN-inducedNF-κB pSer536 levels (Fig. 4E). Collectively, the addition-
al intracellular co-localization of TLR9 and Neu1-MMP-9 complex val-
idated the predicted alliance between TLR9 and Neu1-MMP-9.
If Neu1 and MMP9 form a complex with TLR9, inhibitors against
these enzymes should block ODN-induced phosphorylation of NFκB
in RAW-blue cells. Cells treated with MMP9i and Tamiﬂu inhibited
ODN-induced pNFκB in the cell lysates compared to the ODN-
treated positive control and the β-actin (Fig. 5A). Live cells pretreated
with MMP3i or anti-Neu1 antibody followed with ODN stimulation
showed no reduction of pNF-κB activity in the cell lysates. As
expected, the anti-Neu1 antibody treatment of the live cells wouldnot be internalized into the endosomal compartment to neutralize
Neu1 activity (Fig. 5A).
To conﬁrm Neu1 and MMP9 linkage with ODN-induced NFκB acti-
vation, we also performed the SEAP assay as well. We used MMP3i,
MMP9i, Tamiﬂu and BIM-46174 to determine their inhibitory effects
on ODN-induced SEAP activity in live RAW-blue cells. The data
shown in Fig. 5B–C clearly demonstrate that MMP9i (IC50 =
199 μM) (Fig. 5B), Tamiﬂu (IC50 = 398 μM) (Fig. 5B) and BIM-
46174 (IC50 = 20 μM) (Fig. 5C), but not MMP3i (IC50 N 1000 μM)
(Fig. 5C) dose-dependently blocked the NFκB-dependent SEAP activ-
ity associated with ODN treated live RAW-blue cells.
3.7. Isoforms of neuromedin B GPCR co-immunoprecipitate with TLR-7
and -9 receptors in cell lysates from naive and ligand stimulated
RAW-blue cells
Since neuromedin B receptor antagonist BIM-23127 and the
heterotrimeric G-protein complex antagonist BIM-46174 block
Fig. 3. (A) MyD88 co-immunoprecipitates with TLR7. RAW-blue cells were pretreated with 200 μM Tamiﬂu, 100 μg/mL MMP9i, or 100 μg/mL BIM-23127 for 30 min followed by
10 μg/mL imiquimod or left cultured in media. Cells (1 × 107 cells) are pelleted and lysed in lysis buffer. TLR7 in cell lysates is immunoprecipitated with 1.0 μg of rabbit anti-TLR7
antibodies for 24 h. Following immunoprecipitation, complexes are isolated using protein A or G magnetic beads, washed 3× in buffer and resolved by 8% SDS-PAGE. The blots are
probed for MyD88 (33 kDa) with anti-MyD88 antibodies followed by Clean-Blot IP Detection Reagent for IP/Western blots andWestern Lightning Chemiluminescence Reagent Plus.
The chemiluminescence reaction was analyzed with X-ray ﬁlm. Sample concentration for gel loading was determined by Bradford assay. The data are a representation of one of
three independent experiments showing similar results. (B and C) BIM-46174, Tamiﬂu and MMP9i but not MMP3i inhibit dose-dependently NF-κB-dependent SEAP activity asso-
ciated with imiquimod-treated SEAP reporter-expressing RAW-blue cells. Cells (1 × 105 cells) were treated with different doses of MMP3i inhibitor, MMP9i, Tamiﬂu and BIM46174
for 24 h. The SEAP activity in the culture medium was assessed using QUANTI-Blue substrate. Relative SEAP activity was calculated as fold change of each compound (SEAP activity
in medium from treated cells minus no cell background over SEAP activity in medium from untreated cells minus background). The SEAP activity in the absence of inhibitors is
indicated. The 50% inhibition concentration (IC50) for each inhibitor on SEAP activity induced by imiquimod was determined by plotting the decrease in SEAP activity against
the log of the agent concentration. The data are a representation of mean ± S.E. (n = 3–8 independent experiments as indicated).
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RAW-blue cells (Figs. 2D, 3B and 5C) andMyD88 recruitment associated
with imiquimod-stimulated cells (Fig. 3A), we questioned whether the
bombesin-like receptor, neuromedin B (NMBR) forms a complex with
TLR-7 and -9 receptors. Co-immunoprecipitation experiments using
cell lysates from RAW-blue cells showed that the broad range 63 kDa
isoform of NMBR forms a complex tethered to the cleaved 65 kDa and
full length 180 kDa TLR-9 (Fig. 6A) and cleaved 65 kDa TLR-7 (Fig. 6B)
in naive and 60 min ligand-treated cells. In addition, the 80 kDa isoform
of NMBR co-immunoprecipitated with MMP9, and conversely, the
88 kDa isoform of MMP9 co-immunoprecipitated with NMBR in the
same cell lysates (Fig. 6C). Indeed, it is well known that agonist-bound
GPCRs have been shown to activate numerous MMPs [40], including
MMP9 [41,42]. However, the precisemolecular mechanism(s) underly-
ingGPCR-mediatedMMPactivation is unclear. Perhaps, itmight involve
a conformational change following TLR ligand binding. It has been
reported that the binding of ODN to TLR9 receptors leads to substantial
conformational changes in the TLR9 ectodomain [20,28,43]. The data in
Fig. 6A and B indicate a direct linkage between NMBR andMMP9 at the
ectodomains of TLR-7 and -9 receptors. These interesting ﬁndings are
strikingly consistent with our other report showing a direct linkagebetween NMBR and MMP9 at the ectodomain of TLR4 on the cell
surface [3].
To conﬁrm these ﬁndings, we used BIM-23127 and BIM-46174 to
test their inhibitory effects on SEAP activity associated with ODN and
imiquimod treated RAW-blue cells. As expected, BIM-23127 and
BIM-46174 signiﬁcantly inhibited SEAP activity associated with ODN
(Fig. 6D) and imiquimod (Fig. 6E) stimulation of live SEAP-reporter
RAW-blue cells. The NFκB-dependent SEAP assay shown in Fig. 6F dem-
onstrates that siRNANMBR KD in RAW-blue cells signiﬁcantly inhibited
SEAP activity compared to the WT cells associated with imiquimod
stimulated live cells. Collectively, the data validated the predicted alli-
ance between nucleic acid sensing TLR-7 and -9 receptors and NMBR
in naive macrophage cells. They also support recent evidence for a
novel concept of intracellular GPCR signaling where it suggests new
and intriguing scenarios for the functions of GPCRs in the endocytic
compartments [44,45]. To conﬁrm the location of neuromedin B recep-
tor (NMBR) in the endocytic compartment, we askedwhether the small
GTP binding protein Rab7 which has a role in the late endocytic path-
way and lysosome biogenesis would colocalize with NMBR receptors.
The data in Fig. 6G show this to be the case. NMBR colocalizes with
Rab7 associated with naive RAW-blue cells.
Fig. 4. (A) Neu1 and (B) MMP9 colocalize with TLR9. RAW-blue cells (50,000 cells) were plated on 12 mm circular glass slides in culture media containing 10% fetal calf sera for 24 h
and treated with 10 μg/mL ODN for 60 min or left untreated as controls. Cells were ﬁxed, permeabilized and immunostained with rabbit anti-TLR9, goat anti-Neu1 or goat
anti-MMP9 followed with Alexa Fluor488 donkey anti-rabbit IgG or Alexa Fluor594 donkey anti-goat IgG. Stained cells were visualized using a Zeiss M2 imager with a 40× objec-
tive. To calculate the percentage of colocalization in the selected images, the Pearson correlation coefﬁcient was measured on a total of 15–20 cells per image and expressed as a
percentage using Image J 1.38x software. The data are a representation of one of three independent experiments showing similar results. (C) Neu1 and MMP9
co-immunoprecipitate with TLR9 and conversely (D) TLR9 co-IPs with Neu1 and MMP9. RAW-blue cells are left cultured in media or in media containing 10 μg/mL imiquimod
for 30 min. Cells (1 × 107 cells) are pelleted and lysed in lysis buffer. TLR9, Neu1 or MMP9 in cell lysates from the cells are immunoprecipitated with 1.0 μg of rabbit anti-TLR9,
rabbit anti-Neu1 or rabbit anti-MMP9 antibodies for 24 h. Following immunoprecipitation, complexes are isolated using protein A or G magnetic beads and resolved by 8%
SDS-PAGE. The blots were probed for MMP9, Neu1 or TLR9 with speciﬁc antibodies followed by Clean-Blot IP Detection Reagent for IP/Western blots andWestern Lightning Chemi-
luminescence Reagent Plus. The chemiluminescence reaction was analyzed with X-ray ﬁlm. Sample concentration for gel loading was determined by Bradford assay. The data are a
representation of one of three independent experiments showing similar results. (E) Western blot analysis of ODN-induced phosphorylated NF-κB (Ser(P)536) in cell lysates from
WT and siRNA knockdown (KD) RAW264.7 macrophage cells. WT cells and RAW264.7 siRNA KD Neu1, KD MMP9, KD NMBR and scrambled siRNA cells were treated with 10 μg/mL
ODN for 45 min. Cell lysates from the WT and KD cells were separated by SDS-PAGE, and the blot was probed with phospho-speciﬁc polyclonal rabbit antibody against
NF-κBp65-Ser(P)536. β-Actin was used as an internal control protein for loading of the cytoplasmic cell lysate. Quantitative analysis was done by assessing the density of a band
corrected for background in each lane using Corel Photo Paint 8.0 software. Each bar in the graphs represents the mean ratio of NF-κBp65-Ser(P)536 to β-actin of band densi-
ty ± S.E. (error bars) for 3 independent measurements. p values represent signiﬁcant differences at 99.9% conﬁdence using the Dunnett's multiple comparison test compared
with ligand-treated control cells.
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nist, BIM-46174 signiﬁcantly abrogates imiquimod- and ODN-induced
pro-inﬂammatory cytokines
To further conﬁrm the signaling platform of Neu1 and MMP9
cross-talk in alliance with NMBR GPCR in regulating nucleic acid sens-
ing TLR-7 and -9 receptors, we assessed the Bio-Plex cytokine micro-
array proﬁles in the tissue culture supernatants using the multiplex
bead-based assay which is designed to quantitate multiple cytokines
in single samples. The Bio-Plex suspension array system incorporates
a novel technology using color-coded beads, which permits the si-
multaneous detection of cytokines in a single well of a 96-well
microplate. The 96-well microplate-format Bio-Plex assays are opti-
mized for the Bio-Plex suspension array system which utilizes xMAP
detection technology. By multiplexing, it is possible to quantitatethe level of multiple cytokines in a single well of tissue culture sam-
ple. Here, the chemokine (C–C motif) ligand 2 (CCL2) also referred
to as monocyte chemotactic protein-1 (MCP-1) and TNFα were ana-
lyzed in tissue culture supernatants after 24 h stimulation of
RAW-blue cells with either imiquimod or ODN. Tamiﬂu, MMP9i and
the heterotrimeric G-protein complex antagonist, BIM-46174 signiﬁ-
cantly and dose-dependently abrogated MCP-1 and TNFα secretion
associated with imiquimod- (Fig. 7A) and ODN- (Fig. 7B) stimulated
RAW-blue cells after 24 h.
4. Discussion
The precise molecular mechanism(s) by which nucleic acid sens-
ing TOLL-like receptors are activated is not well understood. For the
majority of cell-surface TLR receptors, dimerization is a prerequisite
Fig. 5. (A) Western blot analysis of ODN-induced phosphorylated NF-κB-Ser(P)311 in cytoplasmic cell lysates from RAW-blue cells. Cells were pretreated with 200 μM Tamiﬂu,
100 μg/mL MMP9i, 100 μg/mL MMP3i or 50 μg/mL anti-Neu1 for 30 min followed by 10 μg/mL ODN or left untreated as medium control. Cell lysates were separated by SDS-PAGE,
and the blot was probed with phospho-speciﬁc polyclonal rabbit antibody against NF-κB Ser(P)311. β-Actin was used as internal control proteins for loading of the cytoplasmic cell
lysate. The data are a representation of one of three independent experiments showing similar results. (B and C) Tamiﬂu, MMP9i and BIM46174 but not MMP3i dose-dependently
NF-κB-dependent SEAP activity associated with ODN-treated SEAP reporter-expressing RAW-blue cells. Cells (1 × 105 cells) were treated with different doses of MMP3i, MMP9i,
Tamiﬂu, and BIM46174 for 24 h, and SEAP activity in the culture medium was assessed using QUANTI-Blue substrate. Relative SEAP activity was calculated as fold change of each
compound (SEAP activity in medium from treated cells minus no cell background over SEAP activity in medium from untreated cells minus background). The SEAP activity in the
absence of inhibitors is indicated. The 50% inhibition concentration (IC50) for each inhibitor on SEAP activity induced by ODN was determined by plotting the decrease in SEAP ac-
tivity against the log of the agent concentration. The data are a representation of mean ± S.E. (n = 2–7 independent experiments as indicated).
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signaling to activate NF-κB. For intracellular TLR3 receptors, they
also form dimers upon interaction of dsRNA. In contrast, the intracel-
lular TLR8 [46] and TLR9 [20,21] appear to exist as preformed naive
signaling dimers. For TLR-9, it is proposed that nucleic acids binding
to two distinct binding sites [21,47] in the ectodomain of the recep-
tors induce conformational changes which enable subsequent signal-
ing. For TLR7 however, the precise mechanism(s) of nucleic acid
action on the receptors is unknown. In this report, we uncovered a re-
ceptor signaling platform by nucleic acid ligands binding to TLR-7 and
-9, which is orchestrated by a novel Neu1 and MMP-9 cross-talk in al-
liance with neuromedin B (NMBR) GPCR. This signaling paradigm
was elucidated to be essential for nucleic acid activation of intracellu-
lar TLR-7 and TLR-9 receptors. In addition, speciﬁc inhibition of Neu1,
MMP9 and the heterotrimeric G-protein complex tethered to both
TLR-7 and -9 receptors in live RAW-blue macrophage cells signiﬁ-
cantly abrogates pro-inﬂammatory cytokines MCP-1 and TNFα. In-
deed, other studies have provided evidence to show that ODN
induces TNFα and TNFR-II at the transcriptional level, and that
these molecular players are involved in MMP9 expression in the
supernatants derived from murine RAW264.7 macrophage cell lineby a TLR9 and a serine/threonine-speciﬁc protein kinase B (Akt)-
mediated mechanism [48,49]. This ODN-induced MMP9 expression
ﬁts well within our novel Neu-1 and MMP9 cross-talk regulating
TLR9 receptors.
Other reports have shown that ODN stimulation of 95D human
lung cancer cells induced the secretion of high-mobility group protein
B1 (HMGB1) dose-dependently [37]. The 95D cancer cell response
to HMGB1 stimulation alone or acting synergistic with ODNmediated
a MyD88-dependent up-regulation of MMP2, MMP9 and cyclin-
dependent kinase-2 (CDK2), which was critically dependent on
35 kDa transmembrane receptor for advanced glycation endproducts
(RAGE) and TLR4 receptors [37]. If ODN-induces HMGB1 secretion in
these cancer cells, it might be possible that HMGB1 may affect
ODN-induced NFκB activation via a TLR4 intermediary in our macro-
phage cells. Other reports provide evidence that this may not be the
case. Secreted HMGB1 can be a trigger of inﬂammation dependent
on the complexes it forms with other molecules [50]. Pure recombi-
nant HMGB1 has no proinﬂammatory activity but can form highly in-
ﬂammatory complexes with ssDNA, LPS, IL-1, and nucleosomes,
which interact with TLR9, TLR4, IL-1R, and TLR2 receptors, respective-
ly [50]. Interestingly, Ivanov et al. have identiﬁed HMGB1 as an
Fig. 6. Neuromedin B receptor (NMBR) co-immunoprecipitates with TLR9 (A) and TLR7 (B), and conversely, TLR7 and TLR9 co-IPs with NMBR. RAW-blue cells were left cultured in
media or in media containing 10 μg/mL ODN or imiquimod for 60 min. Cells (1 × 107 cells) were pelleted and lysed in lysis buffer. NMBR and TLR-7 and -9 receptors in the cell
lysates from the cells were immunoprecipitated with 1 μg of goat anti-NMBR, 1 μg of rabbit anti-TLR7 or rabbit anti-TLR9 antibodies for 24 h. Following immunoprecipitation, com-
plexes were isolated using protein A or G magnetic beads, washed 3× in buffer and resolved by 8% SDS-PAGE. The blots were probed for NMBR with rabbit anti-NMBR or TLR7 or
TLR9 with respective antibodies followed by Clean-Blot IP Detection Reagent for IP/Western blots andWestern Lightning Chemiluminescence Reagent Plus. The chemiluminescence
reaction was analyzed with X-ray ﬁlm. Sample concentration for gel loading was determined by Bradford assay. The data are a representation of one of three independent exper-
iments showing similar results. (C) NMBR co-immunoprecipitates with MMP9, and conversely, MMP9 co-IPs with NMBR in cell lysates from naive and ODN-treated RAW-blue cells.
Cells were left cultured in media or in media containing 10 μg/mL ODN for 30 and 60 min. Cells (1 × 107 cells) were pelleted and lysed in lysis buffer. NMBR and MMP9 receptors in
the cell lysates from the cells were immunoprecipitated with 1 μg of goat anti-NMBR or rabbit anti-TLR9 antibodies for 24 h. Immunoprecipitation was followed as described in (A).
The data are a representation of one of two independent experiments showing similar results. BIM23127 and BIM-46174 inhibit (D) ODN- and (E) imiquimod-induced
NF-κB-dependent SEAP activity in SEAP reporter-expressing RAW-Blue cells. Cells (1 × 105 cells) were treated with 85 μM BIM23127 or 100 μM BIM46174 plus indicated ligand
for 24 h, and SEAP activity in the culture medium was assessed using QUANTI-Blue substrate. The data are the mean ± S.E. (error bars) of three independent experiments. p values
represent signiﬁcant differences at 99% conﬁdence using the Dunnett's multiple comparison test compared with ligand-treated control cells. (F) siRNA NMBR KD RAW-blue cells
inhibit NF-κB-dependent SEAP activity. WT and siRNA NMBR KD RAW-blue cells were treated with imiquimod for 24 h and SEAP activity in the culture medium was assessed
using QUANTI-Blue substrate. Results are mean ± S.E. of three independent experiments. (G) NMBR colocalizes with Rab7. RAW-blue cells (50,000 cells) were plated on 12 mm
circular glass slides in culture media containing 10% fetal calf sera for 24 h and left untreated. Cells were ﬁxed, permeabilized and immunostained with rabbit anti-NMBR and
mouse anti-Rab7 followed with Fluor568 donkey anti-mouse IgG or Alexa Fluor488 donkey anti-rabbit IgG. Stained cells were visualized using a Zeiss M2 imager with a 40×
objective. To calculate the percentage of colocalization in the selected images, the Pearson correlation coefﬁcient was measured on a total of 15–20 cells per image and expressed
as a percentage using Image J 1.38x software. The data are a representation of one of two independent experiments showing similar results.
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the endoplasmic reticulum–Golgi intermediate compartment, has-
tening TLR9's redistribution to early endosomes in response to ODN
[16]. Based on these data, the extracellular HMGB1 was found to ac-
celerate the delivery of ODNs to its receptor, leading to a TLR9-
dependent augmentation of IL-6, IL-12, and TNFα secretion [16].
Using the murine macrophage-like cell lines, RAW 264.7 and
J774A.1, Pisetsky and colleagues have clearly shown that under con-
ditions in which the ODN1826 activated the cell lines, as assessed
by stimulation of tumor necrosis factor-α and interleukin-12, it failed
to cause HMGB1 release into the media [38]. Although unable to in-
duce HMGB1 release by itself, the ODN1826 nevertheless potentiated
the action of LPS in these macrophage cells [38]. The ﬁndings in ourstudies are consistent with these reported studies demonstrating
that TLR9 activation associated with ODN1826-treated macrophages,
HEK-293 and HEK-TKR7-HA cells do not involve HMGB1-induced
TLR4 as an intermediary.
We previously reported that Neu1 is an important intermediate in
the initial process of cell surface TLR ligand-induced receptor activa-
tion and subsequent cellular function [23,24]. The data also provided
evidence for a physiological relevance of Neu1 in regulating endotox-
in LPS induced pro-inﬂammatory cytokines and nitric oxide produc-
tion [24]. Using Neu1 deﬁcient mice, serum pro-inﬂammatory
cytokines were induced in wild-type (WT) and Neu1-deﬁcient mice
responding to LPS after 5 h treatment when compared to basal
serum levels. However, the Neu1-deﬁcient mice produced a
Fig. 7. Bio-Plex cytokine microarray proﬁles in the cell culture supernatants using the multiplex color-coded beads. RAW-blue cells were cultured in 96-well microplate at 30,000
cells per well for 24 h followed by pretreatment with Tamiﬂu, MMP9i and BIM-46174 at the indicated doses in μg/mL for 1 h. The pretreated cells were stimulated for 24 h with
either 20 μg/mL imiquimod (A) or 20 μg/mL ODN (B). The Bio-Plex suspension array system was optimized using the xMAP detection technology. The quantitation of the level of
TNFα and MCP-1 cytokines in a single well of tissue culture sample was assessed from a standard curve. Each bar in the graphs represents the mean ± S.E. (error bars) of three
separate experiments. p values represent signiﬁcant differences at 99% conﬁdence intervals using the Dunnett's multiple comparison test compared with ligand-treated positive
controls.
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neutrophil chemo-attractant) and MIP2 (macrophage inﬂammatory
protein-2) cytokines in response to LPS compared to the wild-type
mice. Using an IL-6 ELISA assay, serum IL-6 was signiﬁcantly reduced
in LPS treated Neu1 deﬁcient mice compared to the WT. The neur-
aminidase inhibitor Tamiﬂu treatment of human monocytic THP-1
cells dose-dependently inhibited IL-6 and TNFα production in re-
sponse to LPS [24]. Flow cytometric analyses conﬁrmed this to be the
case, suggesting that inhibition of the Neu1 sialidase activity by
Tamiﬂu is able to signiﬁcantly inhibit LPS induced pro-inﬂammatory
cytokine IL-6 and TNFα production dose-dependently. In addition,
Tamiﬂu signiﬁcantly inhibited the production of nitric oxide (NO) in
DC2.4 dendritic cells following LPS or killedMycobacterium butyricum
stimulation. Primary bone marrow (BM) macrophage cells from
Neu1-deﬁcient mice exhibited a signiﬁcant reduction in endotoxin
LPS-induced NO production in comparison to WT cohort. Primary
BM macrophage cells derived CathA KI mice (normal Neu1 and inac-
tive cathepsin A) or Neu4 knockout (KO) mice exhibited LPS induced
NO production comparable to the WT cohort [24]. Collectively,
proinﬂammatory IL-6 and TNFα cytokines and nitric oxide production
associatedwith endotoxin LPS activation of cell surface TLR4 receptorsare partially dependent on Neu1 sialidase in conjugation with MMP-9
and GPCR signaling [24,35]. The data in this report provide further ev-
idence to support an identical signaling platform in regulating nucleic
acid-induced endosomal TLRs to produce TNFα and MCP-1 cytokines.
It has become evident that TLRs require additional proteins to be ac-
tivated by their respective ligands. For an example, not only is CD14 as-
sociated withMyD88-dependent TLR4 receptors on the cell surface, but
it also constitutively interacts with the MyD88-dependent TLR7 and
TLR9 receptors [51]. It was found that CD14 was necessary for TLR7-
and TLR9-dependent induction of proinﬂammatory cytokines in vitro
and for TLR9-dependent innate immune responses in mice. In addition,
the absence of CD14 led to reduced nucleic acid uptake inmacrophages.
Using various types of vesicular stomatitis virus, the report showed that
CD14 is dispensable for viral uptake but is required for the triggering of
TLR-dependent cytokine responses [51]. These ﬁndings suggest that
CD14 has a dual role in nucleic acid-mediated TLR activation whereby
it can promote the selective uptake of nucleic acids, and at the same
time, it acts as a co-receptor for endosomal TLR activation. Interestingly,
others have demonstrated another important role for CD14 [52]. It also
associates with Gi (inhibitory class) and Go (olfactory class) α subunits
of G-proteins. The heterotrimeric G proteins were shown to have a
2104 S. Abdulkhalek, M.R. Szewczuk / Cellular Signalling 25 (2013) 2093–2105speciﬁc regulatory function in CD14-associated LPS-induced mitogen-
activated protein kinase (MAPK) activation and cytokine production
in normal human monocytes [52]. A signiﬁcant decrease in LPS-
induced activation of c-Jun-N-terminal kinase (JNK) and p38 kinase
was reported with a subsequent loss in the production of TNF-α when
THP-1 human monocyte cells were pretreated with Gαi-sensitive per-
tussis toxin [53]. Using the knockout mouse models of Gαi2−/− and
Gαi1/3−/− proteins, Fan et al. [54] showed a signiﬁcant decrease in TLR
ligand-mediated TNF-α and IL-10 production in peritoneal macro-
phages of the knockoutmice compared towild-type cohort. These ﬁnd-
ings suggest a regulatory role for Gαi proteins in TLR signaling, which is
potentially dependent on a cellular phenotype [55]. In themurine RAW
264.7macrophage cell line and primarymurinemacrophages, G protein
dysregulation induced by wasp venom-derived peptide mastoparan
caused a signiﬁcant inhibition in LPS-induced TLR4-, but not in
TLR2-mediated gene expression [56]. The data in the present report
support a unique organizational GPCR signaling platform as the initial
processing stage for GPCR signaling in mediatingMMP9 activation to in-
duce Neu1, all of which form a tripartite complex with TLR-7 and -9
receptors. This signaling paradigm was essential for subsequent down-
stream cellular signaling and the production of pro-inﬂammatory cyto-
kines. In the present report, the involvement of heterotrimeric
G-protein complex in TLR ligand-mediated receptor function has also
been shown for endosomal TLRs. Using siRNA NMBR knockdown cells
and neuromedin B receptor antagonist BIM-23127 and the hetero-
trimeric G-protein complex antagonist BIM-46174, the results provided
evidence for a signiﬁcant diminution of NF-κB activation and reduced
MyD88 recruitment associated with imiquimod- and ODN- stimulated
RAW-blue cells. Collectively, the data validated the predicted alliance be-
tweennucleic acid sensing TLR-7 and -9 receptors andNMBRGPCR local-
ized in the late endocytic lysosomal pathway of naive macrophage cells.
This TLR signaling paradigm also predicts that endosomal TLR receptors
are in alliance with a functional GPCR signaling complex.
In support of this premise, our studies and others have provided
important evidence to show that the crosstalk between GPCR and
TLR signaling pathways and the GPCR signaling molecules may have
uncharacterized functions in macrophage cells [1–3,57]. Recently,
we have reported that GPCR agonists bombesin, bradykinin,
lysophosphatidic acid (LPA), cholesterol, angiotensin-1 and -2, but
not thrombin induce Neu1 activity in live macrophage cell lines and
primary bone marrow macrophage cells from wild-type (WT) mice
but not from Neu1-deﬁcient mice [3]. Using immunocytochemistry
and NFκB-dependent secretory alkaline phosphatase (SEAP) analyses,
bombesin induced NFκB activation in BMC-2 and RAW-blue macro-
phage cells, which was inhibited by MyD88 homodimerization inhib-
itor, Tamiﬂu, galardin, piperazine and anti-MMP-9 antibody [3]. The
bombesin-related receptor, neuromedin B (NMBR), formed a com-
plex with TLR4 and MMP9. Silencing MMP9 mRNA using siRNA trans-
fection of RAW-blue macrophage cells markedly reduced Neu1
activity associated with bombesin-, bradykinin- and LPA-treated
cells compared to the untreated controls [3]. Interestingly, the data
in the report indicated that the three different isoforms of NMBR
are tethered to TLR-4 receptors, but it was the 80 kDa isoform of
NMBR which formed a complex with MMP-9, making it readily avail-
able to activate MMP-9 on the cell surface of naive macrophage cells.
Unexpectedly, the 63 and 80 kDa isoforms of NMBR are eventually
lost over time with LPS treatment. In the present study, we have
found that the 63 kDa isoform of NMBR is also tethered to the cleaved
65 kDa TLR-7 and the cleaved 80 kDa TLR9 receptors with no loss
with ligand-stimulation of the cells over 60 min. The reason(s) for
this differential activity of the NMBR isoforms is unknown. More im-
portantly, the similarity of the mechanism NMBR in alliance with
Neu1 and MMP9 regulating TLR4 on the cell surface and the intracel-
lular TLR7 and TLR9 in the endosomal compartments is striking. The
data shown in Fig. 1 suggest that the MMP9/Neu1 complex is sepa-
rately tethered to either TLR-4, -7 or -9 receptors and it does notshuttle from the cell surface to the endosomal compartments and
vice-versa. Firstly, the NMBR/MMP9/Neu1 tripartite complex is al-
ready present on TLR4 [2] and TLR-7 and -9 receptors in naive,
unstimulated cells. Secondly, imiquimod and ODN stimulation of
HEK-293 and HEK-TLR7-HA induce NFκB activation in the absence
of the TLR4 intermediary. What we do not understand is how and
when this novel regulatory signaling complex is formed on these
receptors.
The connection between NMBR GPCR and Neu1/MMP9 is intrigu-
ing. The diverse multiple actions of GPCRs regulating TLRs and its
translation to human disease require further investigations to uncov-
er their functional roles in cellular signaling [1]. Accordingly, the reg-
ulation and sorting of GPCRs by endocytic membrane trafﬁcking and
its potential implications are eloquently reviewed by Hanyaloglu
and colleagues [58,59] and Marchese et al. [60]. Indeed, achieving a
coordinated regulation of multiple receptor-mediated signaling is
one of the mandates for GPCRs which represent the largest family of
signaling receptors expressed in animals, and they respond to a
wide range of stimuli. The evidence suggests an unprecedented de-
gree of speciﬁcity and plasticity in the cellular regulation of mamma-
lian GPCRs by endocytic membrane trafﬁcking [58]. The diverse
physiological roles played by GPCRs are noteworthy of further
study. For examples, there is evidence for disordered GPCR signaling
in various pathological conditions such as (a) dysregulation of GPCR
function [61], (b) the ‘loss of function’ mutation or the ‘gain of func-
tion’ mutation [62], (c) constitutively active GPCRs especially those
that are tumorigenic in vitro and in animal models of human disease
that cause syndromes of hyperfunction and/or tumors in humans in-
cluding diseases involving infectious viral agents [61,63] and (d) the
mutant GPCRs as a cause of human diseases [64]. To date, over 600
inactivating and almost 100 activating mutations in GPCR have been
identiﬁed, which are responsible for more than 30 different human
diseases. The number of human disorders is expected to increase
given the fact that over 160 GPCRs have been targeted in mice [64].
Perhaps, one mechanism by which ligand-induced TLR activation
could modify GPCR signaling is by altering the expression of regulator
of G protein signaling (RGS) proteins [65]. Other reports have shown
that GPCR sphingosine 1-phosphate S1P1 and S1P3 expression was
induced by LPS in human gingival epithelial cells (HGEC), and this el-
evated expression enhanced the inﬂuence of S1P in its cooperation
with TLR4 to increase cytokine production [66]. Furthermore, the
relationship between GPCR-signaling and TLR has been shown for
(a) CC chemokine ligand-2 synergizing with the non-chemokine
GPCR ligand fMLP in monocyte chemotaxis [67], (b) beta-arrestin 2
involvement in complement C1q expression in macrophages [68],
(c) leukotriene B4 (LTB4) receptor BTL1 reduction of SOCS1 inhibition
of MyD88 expression in mouse macrophages [69] and (d) GPCR-
derived cAMP signaling inﬂuencing TLR responses in primary macro-
phages through peptide disruptors of A-kinase anchoring protein
(AKAP10) involving prostaglandin E2 (PGE2) [70].
Collectively, the parameters controlling interactions between the
TLRs and their ligands still remain poorly deﬁned. The present report
proposes that Neu1 is an important intermediate in the initial process
of endosomal TLR nucleic acid-induced receptor activation and subse-
quent cellular function. Central to this process is that Neu1 andMMP9
in alliance with the 63 kDa isoform of GPCR NMBR receptor are sepa-
rately tethered to TLR-7 and -9 receptors in naive TLR-expressing
cells. This paradigm signiﬁes an unprecedented molecular GPCR sig-
naling platform of a Neu1 and MMP9 cross-talk in alliance with
endosomal TLR-7 and -9 that is essential for nucleic acid activation
of endosomal TLRs and subsequent cellular signaling.Competing ﬁnancial interests
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